Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Receivables (2016 - 2025)

Historic Receivables for BioCorRx (BICX) over the last 16 years, with Q3 2025 value amounting to $955957.0.

  • BioCorRx's Receivables rose 5214.01% to $955957.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $955957.0, marking a year-over-year increase of 5214.01%. This contributed to the annual value of $152532.0 for FY2023, which is 3966.39% down from last year.
  • Latest data reveals that BioCorRx reported Receivables of $955957.0 as of Q3 2025, which was up 5214.01% from $204970.0 recorded in Q2 2025.
  • BioCorRx's 5-year Receivables high stood at $1.1 million for Q2 2022, and its period low was $1500.0 during Q1 2021.
  • Over the past 5 years, BioCorRx's median Receivables value was $194911.0 (recorded in 2023), while the average stood at $346456.1.
  • In the last 5 years, BioCorRx's Receivables tumbled by 9880.0% in 2021 and then surged by 7159800.0% in 2022.
  • BioCorRx's Receivables (Quarter) stood at $112718.0 in 2021, then surged by 124.28% to $252804.0 in 2022, then crashed by 39.66% to $152532.0 in 2023, then soared by 311.94% to $628340.0 in 2024, then skyrocketed by 52.14% to $955957.0 in 2025.
  • Its last three reported values are $955957.0 in Q3 2025, $204970.0 for Q2 2025, and $306720.0 during Q1 2025.